Compare Amgen, Inc. (AMGN) vs Allbirds Inc (BIRD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Allbirds Inc — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Allbirds Inc trades at $3.11 (market cap $27.52M). The key difference: Amgen, Inc. is far larger — about 7126.5× Allbirds Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Allbirds Inc pays none. Which is the better fit depends on your goals.
| AMGN | BIRD | |
|---|---|---|
Market Cap | $196.12B | $27.52M |
Sector | Health | Consumer Cyclical |
52-Week High | $388.16 | $16.99 |
52-Week Low | $271.18 | $2.39 |
Enterprise Value | $241.41B | $46.39M |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
BIRD (Smartbird) trades at $3.13, down 9.54% today, reflecting volatility following its pivot from footwear to AI infrastructure. The stock shows a bearish technical signal with mixed oscillators, while fundamentals reveal persistent losses: revenue declined to $152.47M in 2025 with a net margin of -53.36%. Recent news highlights the company's rebranding and new CEO appointment, driving significant stock movements amid investor speculation on its AI strategy.
The outlook is highly speculative, with opportunity stemming from potential AI business execution, but substantial risks remain due to negative profitability, cash burn, and reliance on a unproven new direction. Analyst consensus is cautious, with 78.57% hold ratings, indicating skepticism about near-term turnaround prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Allbirds Inc
Allbirds Inc is a global lifestyle brand that innovates with naturally derived materials to make footwear and apparel products. Its primary source of revenue is from sales of shoes and apparel products in its directly owned digital and physical retail channels.
Read more on BIRD →
